In the fall of 1890, an athletic, self-possessed, and thoughtful 17-year-old girl, who had just returned from an adventurous trip to Alaska where she had hurt her hand in a trivial accident, went to see a young, innovative surgeon in his new practice in New York City. Barely out of Harvard Medical School, he was a rising star in New York surgical circles, and the young woman asked him for help with her poorly healing, swollen, and naggingly painful injury. This visit had a far-reaching effect on cancer research, American philanthropy, and the career of the young man, William Coley, MD (1862-1936, Figure 1). The patient, Elisabeth Dashiell, confidant and close friend of John D. Rockefeller, Jr, was diagnosed by Coley with a highly aggressive round cell sarcoma, and despite radical surgery and in spite of Coley’s undoubtedly fine surgical skills and intensive care, a rapid progression of the cancer, immense suffering, and Elisabeth’s death a few months later could not be prevented.

The experience of the swift, fatal course and of the insufficiency of surgery in even the finest and most modern American hospital left Coley deeply shaken—and determined to find a treatment for this dreadful disease. It also was the starting point of Coley’s lifelong friendship with Rockefeller, whose philanthropic work was inspired by Elisabeth’s death, leading to the foundation of the Rockefeller University.1

Coley went on to develop the first immunological cancer treatment, attempting to cure cancer with fever, and thereby founded the field of tumor immunology. He began with an investigation of all case histories of sarcoma at the New York Cancer Hospital (later Memorial Sloan-Kettering). He stumbled on the record of a 31-year-old Fred K. Stein, who was afflicted with a round cell sarcoma on the neck that had recurred 5 times after surgical removal until it was considered inoperable; the case had been declared hopeless when the man contracted a severe erysipelas infection (caused by Streptococcus pyogenes) that spread rapidly over the neck and face and was accompanied by a raging fever. A second attack followed 2 weeks later. In the course of these attacks, the sarcoma disappeared entirely. Seven years later, Coley tracked Stein down on the Lower East Side, where he still enjoyed excellent health and had only a scar below his ear left to show where the “inoperable” sarcoma had been.1,2

FEVERISH INFECTIONS AND SPONTANEOUS REMISSION

Since the 18th century, spontaneous remissions of cancer—altogether a very rare event—have been observed repeatedly in connection with febrile infectious diseases, especially those of bacterial origin.1,3-5 In 1866, Busch described complete remissions occurring under erysipelas covering the tumor.3 In 1882, Fehleisen induced tumor remission with the inoculation of streptococci causing erysipelas.6 The French physician Dussosoy dressed an ulcerated breast carcinoma with charpie soaked with gangrenous discharge and inoculated gangrenous matter; the tumor was said to have disappeared.4 In the 1950s, Huth described 24 remissions of leukemia after bacterial infections.7 Of a total of 224 spontaneous remissions of cancer reviewed by Stephenson, 62 had occurred under infection or persistent fever and 77 under “reticuloendothelial stimulants.”8 Of 68 spontaneous remissions of metastatic melanoma, 21 occurred concurrent to infections and 11 to immunoactive interventions (eg, vaccination, application of antibodies, tumor cells, Bacillus Calmette-Guérin [BCG]).9 Of 86 spontaneous remissions of lymphoma, 3 occurred after bacterial or viral infections and 12 after termination of immunosuppressive treatment.10 Of 98 children with Hodgkin’s lymphoma, 3 contracted measles that led to tumor remission.11 Among 21 patients with spontaneous regression of colorectal cancer, 6 occurred under septic complications or febrile
pneumonia. A profound and comprehensive documentation included 449 cases of spontaneous or induced bacterial or viral infections in cancer patients that led to remission in most cases. For instance, of 163 patients with inoperable carcinoma or sarcoma who had pyogenic infections, a complete regression had occurred in 37 who were followed for 5 to 46 years; in 54 patients, the tumor had regressed completely but was followed for less than 5 years or diagnosed only clinically; 13 patients had shown no response; the remaining patients had a tumor remission with an unknown long-term outcome or had died.

Coley thoroughly reviewed the literature available at that time and found 38 reports of cancer patients with accidental or iatrogenic feverish erysipelas. In 12 patients, the sarcoma or carcinoma had completely disappeared; the others had substantially improved. Coley decided to attempt the therapeutic use of iatrogenic erysipelas when the next patient with an infaust and hopeless condition was referred to him: Signor Zola, a 35-year-old Italian, had a recurrent and now inoperable sarcoma of the neck and the tonsil (Figure 2). The size of a hen’s egg, it almost completely blocked the pharynx. The patient was in a bad condition—cachectic, with liquids regurgitated through the nose—and was expected to live only a few weeks. Coley inoculated Streptococcus pyogenes every 3 to 4 days for months but only induced slight local and systemic reactions, leading to some tumor shrinkage and improvement of the general condition but not to erysipelas or to disappearance of the tumor. When the inoculations were paused, the tumor continued to grow and shrank again during the next inoculations. Dissatisfied with this course, Coley managed to get bacteria from Robert Koch’s laboratory in Germany. Within 1 hour of the bacteria being injected directly into the neck tumor, the patient developed chills, pain, nausea, vomiting, and a high fever (105°F), and after 12 hours, a typical erysipelas stretched over the tumor of the neck, extended over the face and head, and met on the other side. The attack lasted 10 days. The neck tumor changed promptly, got paler and softer, began to break down on the second day, discharged a caseous material until the last day, and had disappeared after 2 weeks. The tonsil tumor regressed but never disappeared completely and remained as a hard, fibrous mass. The patient rapidly gained strength and appetite appeared completely and remained as a hard, fibrous mass. The patient rapidly gained strength and appetite appeared completely and remained as a hard, fibrous mass. The patient rapidly gained strength and appetite appeared completely and remained as a hard, fibrous mass.

Figure 2 Signor Zola, who survived another 8 years after being treated by Coley in 1891. Reprinted with permission from the Cancer Research Institute.

Mixed bacterial vaccine

Different lessons were learned: A fulminant attack of erysipelas can induce dramatic and complete tumor remission; a mere injection of Streptococcus pyogenes without a full erysipelas can improve the disease and induce some tumor shrinkage but does not lead to complete, durable tumor remission; it is not easy to induce a full erysipelas attack by streptococci; and erysipelas is a severe, life-threatening disease. These difficulties led Coley to try cultures sterilized by heating or filtration, which produced little effect. Inspired by the animal experiments of Rogers, he mixed them with toxins of gram-negative Serratia marcescens and thus created the mixed bacterial vaccine (MBV). The first patient treated with MBV was a 16-year-old German with an inoperable spindle cell sarcoma on the abdominal wall, 6.5 x 5.25 x 5 inches, attached to the pelvis, and infiltrating the bladder. The patient was in bad condition when the MBV treatment was started. The intratumoral injections were followed by a temperature increase of 0.5° to 6°, with tachycardia, chill, extreme trembling, and severe headache. At times, the tumor was enlarged on the days following the injection but then gradually decreased over the next months and finally disappeared. The man regained good health and stayed healthy without a recurrence until he suddenly died of myocarditis 26 years later in a subway station.

Coley, who meanwhile became a staff member and later chief of the Bone Cancer Department of the New York Cancer Hospital—the second in the world dedicated to the treatment of cancer and supported by wealthy families—successively developed and improved MBV treatment, the first official immunotherapy for cancer. Especially in sarcomas but also in other cancer types, long-term remissions could be
achieved with MBV alone, without surgery or radiotherapy (Table 1).

The patients were tracked down, and their long-term outcomes were carefully documented over years and decades, up to 88 years in one case. The documentation was done for the most part by William Coley’s daughter, Helen Coley-Nauts (1907-2000), founder of the New York Cancer Research Institute. She conscientiously and comprehensively documented all the patients treated with MBV by her father and colleagues and tried to keep track of all of them. In 1953, she published her first detailed analysis, which attracted worldwide attention. She had collected 1200 cases treated with MBV and reported more than 270 patients with inoperable cancer achieving a complete remission with MBV; the follow-up time stretched up to 45 years. Cases were classified into “successes” (ie, complete remission with no recurrence during later years) and “failures”: those cases that also included complete remissions but in which cancer recurred later.

In 1959, a survey was published on all MBV-treated cases with soft tissue sarcoma (except lymphosarcoma), osteosarcoma, Ewing’s tumor, reticulum cell sarcoma, ovarian carcinoma, cervical carcinoma, testicular tumor, renal tumor, multiple myeloma, colorectal carcinoma, breast carcinoma, and melanoma, with similar results. MBV was usually injected intramuscularly and locally intra- or peritumorally; intravenous application was not generally recommended due to safety concerns. Patients developed shaking chills followed by fever (102-105 ºF) lasting up to 12 to 24 hours. The injections were repeated first every day and then on alternate days with increasing dosage. High and consistent fever plus the local inflammation at the tumor site were regarded as essential for therapeutic success. Treatment success was obvious within a few days: the tumors became paler, softer, and movable, then regressed or opened and discharged a caseous secretion or just regressed. If these reactions did not occur within 1 to 4 weeks, MBV was regarded as ineffective; nevertheless, it often still improved the patient’s general condition, reduced pain, or improved appetite. To achieve a durable remission and prevent relapses, the treatment was continued for a long time (usually months). Patients were treated according to their individual constitution and reaction in order to increase the effectiveness and to minimize the risks. The recurrent chills and the induced fever over weeks and months were strenuous for the patients, many of whom were severely ill. In 1000 treated patients, 6 fatal complications were observed due to embolism, acute nephritis, hemorrhage (if the tumor had grown into a blood vessel), or the injection of too large initial dosages by inexperienced physicians. Otherwise, MBV was largely safe.

Up to 15 different preparations of MBV existed, but not all were potent enough to induce high fever and durable remissions. This was particularly the case with the commercial preparations used mostly outside of New York. In one instance, Coley was contacted by a colleague who had treated a lymphosarco-

### Table 1: Patients With Inoperable Cancer Treated With Mixed Bacterial Vaccine Alone Before 1940

| Type of Cancer                        | Total | Patients With Complete Tumor Remission | No Tumor Response |
|--------------------------------------|-------|---------------------------------------|-------------------|
|                                      |       | Follow-up                              |                   |
|                                      |       | > 20 y | 10-20 y | 5-10 y | < 5 yb |
| Soft tissue sarcomas                 | 84    | 17    | 12     | 11     | 12     | 32 |
| Lymphosarcomas (lymphomas)          | 33    | 8     | 7      | 4      | 4      | 10 |
| Osteosarcoma                         | 3     | 0     | 0      | 0      | 1      | 2  |
| Ewing’s tumor/reticulum cell sarcoma | 1     | 1     | 0      | 0      | 0      | 0  |
| Ovarian carcinoma                    | 4     | 1     | 0      | 0      | 2      | 1  |
| Cervical carcinoma                   | 2     | 1     | 0      | 0      | 1      | 0  |
| Testicular tumor                     | 14    | 1     | 2      | 3      | 3      | 5  |
| Renal tumor                          | 8     | 1     | 1      | 1      | 1      | 4  |
| Multiple myeloma                     | 1     | 0     | 0      | 1      | 0      | 0  |
| Colorectal carcinoma                 | 1     | 0     | 0      | 0      | 0      | 1  |
| Breast carcinoma                     | 13    | 0     | 0      | 2      | 6      | 5  |
| Melanoma                             | 6     | 0     | 1      | 0      | 3      | 2  |

a Values indicate number of patients with or without tumor response, duration of follow-up with no indication of relapse. b Or relapse within 5 years.
ma patient with high doses of a commercial product without any response. When Coley provided him with vaccines from his own supply, the patient reacted to the very first injection with high fever, chills, and subsequent tumor remission and was disease-free until he died of heart disease 33 years later.30

After Coley’s death in 1936, MBV treatment was continued but clinical interest diminished in favor of radiotherapy and chemotherapy, which promised a breakthrough in cancer treatment comparable to antibacterial treatment. In 1961, the thalidomide tragedy occurred and gave rise in the United States to the Kefauver Harris Amendment, which applied strict requirements to preclinical and clinical investigations of new treatments. Although it had been used for 70 years, MBV was at that time classified as a new treatment, necessitating expensive investigations for drug licensing. As MBV is a natural substance and was therefore not patentable, the investment of millions of dollars for testing was unattractive for any drug company. As for academic institutions, other topics were more appealing than an old bacterial treatment dealing essentially with “dirt.”

Still, some small prospective studies were conducted; MBV treatment was, however, increasingly standardized, applied less aggressively, and the vaccines less potent (Helen Coley-Nauts, oral communication, December 1996). Furthermore, the included patients were often pretreated with chemotherapy or radiotherapy, which substantially alters the immune system and therefore modifies the response to an immunomodulating treatment.17

In one randomized controlled trial (RCT), MBV-treated patients with advanced, metastatic cancer (n = 34) showed 7 subjective and 9 objective responses, 3 of which were complete remissions (partly verified by later autopsy); in the control group (n = 37), which was administered typhoid vaccines, one improvement was reported.38 Of 93 patients with advanced cancer in a single-arm MBV study, 30 had a tumor remission (partly verified by later autopsy), 20 reported subjective improvements, and the remaining 43 had no change.39 In a study of 7 patients with inoperable cancer, no remissions were found.42 In a small RCT, patients with advanced non-Hodgkin’s lymphoma who were treated with MBV in addition to chemotherapy showed higher response rates than control patients without MBV (complete remissions 85% vs 44%, respectively), and survival was significantly longer.43-45 Patients with liver cancer showed better survival (trend) in an RCT when chemotherapy (partly also radiotherapy) was combined with MBV.46 In a study on metastatic melanoma, of 15 patients receiving MBV, 3 had a complete remission (20%) lasting at least 15, 21, and 32 months.39 Other studies on MBV primarily investigated immunomodulation and tolerability.47,48 Recently, 128 cases treated with MBV between 1890 and 1960 were matched with 1675 control patients from the Surveillance Epidemiology End Results (SEER) cancer registry who received a cancer diagnosis in 1983. The survival rates were not significantly different, despite the tremendous advances in surgical techniques and modern medicine with which patients in the SEER group were treated (Table 2).49

### TABLE 2 Survival of Patients Treated (1890-1960) With Mixed Bacterial Vaccine (MBV) Matched With Patients From Surveillance Epidemiology End Results (SEER) Diagnosed in 1981

| Tumor type          | Median Survival, y | 10-y Survival Rate |
|---------------------|--------------------|--------------------|
|                     | MBV                | SEER               |
| Kidney cancer       | 6.5                | 5                  |
| Ovarian cancer      | 10                 | 8                  |
| Breast cancer       | 5                  | 7                  |
| Soft-tissue sarcoma | 10                 | 8                  |

*Matching criteria: site, stage, treatment status (ie, no radiotherapy), age, sex, ethnicity.43

### INFECTIOUS DISEASES AND SUBSEQUENT CANCER

Clinicians frequently have claimed that the anamnesis of cancer patients revealed fewer feverish infections compared to other patients. This gave rise to numerous epidemiological investigations,50 which predominantly show an inverse association between various acute infectious diseases or fever and cancer risk (Table 3).51-88 The risk is further reduced with increased frequency of infections and if fever is involved. Somehow, these events affect cancer immune surveillance, which seems to be—conversely—negatively affected by the risk factors supporting cancer growth.59

Often, a better outcome is also reported in cancer patients who had postoperative infections. However, the corresponding studies usually refer to very small sample sizes, limiting their validity. Potential confounders prevalent especially after postoperative infectious complications are another reason for these altogether conflicting results. For instance, several studies reported longer survival in patients with empyema after lung cancer surgery.90-91 These observations prompted an RCT in which BCG was applied intrapleurally after resection of lung cancer, which led to a substantial reduction of recurrences in early stages but no difference in advanced stages of the cancer.94 Two studies found no difference in survival after empyema,95,96 and one study showed a slightly negative effect.97 In colon cancer (stage I), one study found better survival in patients with postoperative infections,98 another study found no difference,99 and a third study found increased recurrences (with, however, an altogether high prevalence of infections).100 In melanoma, after local wound infection, decreased recurrences were reported, but there was no difference in survival.101 Survival also was increased in osteosarcoma patients after postoperative infection.102 In patients with breast and head and neck cancer, however, rates of recurrence were higher and survival partly reduced after a postoperative increase in temperature or wound infection.103-105

Interestingly, in contrast to acute inflammation,
| Infectious Disease or Condition | Case/Control | Cancer Site | History of Infectious Diseases in Cancer Patients/Year | Cancer Risk After Infectious Diseases | Reference No. |
|--------------------------------|-------------|------------|-----------------------------------------------------|--------------------------------------|---------------|
| Childhood disease, infectious diseases | 241/— | Gastrointestinal | No infectious disease as child in 180 patients, as child and as adult in 99 patients | 1910 | 51 |
| Childhood disease, infectious diseases | 300/300 | Multiple | No infectious disease in 113 cancer patients vs 16 control patients | 1934 | 52 |
| Childhood disease, infectious diseases | 232/2444 | Multiple | Fewer infectious diseases, especially childhood diseases | 1936 | 53 |
| Tonsillectomy<sup>a</sup> | 831/9990 | Upper aerodigestive tract | Fewer tonsillectomies | 1960 | 54 |
| Tonsillectomy<sup>a</sup> | 542/5020 | Upper aerodigestive tract | Fewer tonsillectomies | 1963 | 55 |
| Mumps, measles, rubella | 97/97 | Ovarian | Less mumps and rubella | 1966 | 56 |
| Mumps | 36/150 | Ovarian | No association | 1969 | 57 |
| Typhoid fever<sup>b</sup> | 5460<sup>b</sup>/Viennese population | Multiple | Lower cancer mortality in survivors of typhoid fever 1945-1947 | 1970 | 58 |
| Multiple (febrile disease, other diseases) | 150/150 | Multiple | Less fever (1% vs 13%), fewer doctor visits (15% vs 45%), less hospitalization (5% vs 12%) | 1970 | 59 |
| Pneumonia, influenza | 399/995 | Ovarian | Less pneumonia and influenza | 1974 | 60 |
| Tonsillectomy<sup>a</sup> | 305/305 | Leukemia (in children) | Fewer tonsillectomies | 1975 | 61 |
| Tonsillectomy<sup>a</sup> | 752/752 | Leukemia | Fewer tonsillectomies | 1976 | 62 |
| Mumps, measles, chicken pox, rubella | 300/600 | Ovarian | Fewer infections (reduced risk of ovarian cancer in history of infections: RR 0.47-0.86) | 1977 | 63 |
| Tonsillectomy<sup>a</sup> | 1415/1415 | Lung | Fewer tonsillectomies | 1978 | 64 |
| Rubella, measles, mumps | 197/197 | Ovarian | Overall, no difference; more peripubertal rubella and measles (12-18 y), less during childhood years | 1979 | 65 |
| Immunizations, infectious diseases | 33/99 | Rhabdomyosarcoma (in children) | Fewer immunizations, more preventable (with immunization) infectious diseases | 1982 | 66 |
| Multiple, fever | 110/126 | Multiple | Less fever, fewer colds and organic infections | 1983 | 67 |
| Measles | 252/230<sup>c</sup> | Multiple | More tumors in people with no measles rash despite immunoglobulin G measles antibody | 1985 | 68 |
| Multiple | 492/480 | Leukemia (in children) | Reduced risk of leukemia after serious infectious diseases: RR 0.6 | 1986 | 69 |
| Common cold | 120/239 | Multiple | No association | 1986 | 70 |
| Fever >3 days, herpes | 204/1353<sup>d</sup> | Multiple | Reduced cancer risk after febrile diseases | 1987 | 71 |
| Multiple | 255/485 | Multiple | Reduced cancer risk after cold/influenza (OR 0.18-0.23) or febrile abdominal influenza (OR 0.15-0.23) but not after childhood diseases | 1991 | 72 |
| Childhood disease, febrile infectious diseases | 139/271 | Melanoma | Reduced risk of melanoma after chronic infectious diseases (OR 0.32), febrile abscesses, wound infections (OR 0.21), influenzacold (OR 0.32), trivial febrile diseases (OR 0.34). No association with childhood disease | 1992 | 73 |
| Chicken pox, shingles | 462/443 | Glioma | Fewer chicken pox (OR 0.4) and shingles (OR 0.5) | 1997 | 74 |
| Febrile childhood disease | 379/379 | Multiple | Reduced cancer risk after febrile childhood diseases (non-breast cancer OR 0.27, especially rubella, chicken pox) | 1998 | 75 |
| Infectious diseases | 255/485 | Multiple | Decreased mortality from infectious diseases (1895-1947) paralleled and followed by increased mortality from cancer (1895-1990) | 1998 | 76 |
| Multiple (severe or less severe, fever) | 603/627 | Melanoma | Reduced risk of melanoma after febrile infections: tuberculosis (OR 0.16), Staphylococcus aureus (OR 0.54), sepsis (OR 0.23), flu (OR 0.65), pneumonia (OR 0.45); dose-response relationship | 1999 | 77 |
| Infectious diseases | 1509/2493 | Glioma, meningioma | Reduced risk of glioma and meningioma after infectious diseases (RR 0.72 and 0.73) | 1999 | 78 |
chronic inflammation increases cancer risk and can affect every aspect of tumor development. Many chronic viral, bacterial, and parasitic infections are a risk factor for developing cancer: Helicobacter pylori in mucosa-associated lymphoid tissue lymphomas, Epstein-Barr virus in lymphoma or nasopharyngeal cancer, hepatitis B and C virus in liver cancer, herpes virus type 8 in Kaposi sarcoma, human papillomavirus in cervix or anogenital cancer, Schistosoma in bladder cancer, and others. About 15% to 20% of cancers worldwide are attributed to these infectious agents. Noninfectious chronic inflammatory diseases also are a major risk factor for cancer. Examples include inflammatory bowel disease and colon cancer, bronchitis and lung carcinoma, reflux esophagitis and esophageal cancer. Sustained inflammation seems to be the result of an individual's inability to eliminate infection and restore immune homeostasis. Immune and inflammatory cells as well as cytokines can have antitumor- and tumor-promoting functions, depending on the context.

**INITIATION OF CANCER IMMUNOTHERAPY**

In Coley’s era, the scientific and medical community lacked the prerequisite knowledge to understand his treatment. The intellectual environment was incapable of making scientific sense of tumor remissions after application of bacterial toxins. Hardly anything was known about the immune system. The notion of cellular immunity was completely out of favor. Regarding inflammation, almost everybody agreed that this was a deleterious reaction of no benefit for the host, a purely passive response to the insulted organism. So it is not surprising that Coley—a respected surgeon but not a trained scientist—received harsh opposition. For decades after Coley’s death, fighting cancer with a host response was regarded as impossible; for a long time, investigating tumor immunity was considered a scientific red-light district, “a seedy intellectual neighborhood of fantasy and wishful thinking, a landscape littered with the hulks of abandoned hypotheses and charred reputations.” It was a biological minefield, capable of ruining careers. Even in the 1980s, the concept of clinical tumor immunity was regarded as consisting of laboratory artifacts.

Still, Coley’s work substantially inspired research, and his observations were a main impulse for later tumor immunology. Shortly after Coley’s death, Shear discovered lipopolysaccharides (LPS), a component from the membrane of *Serratia* that induced necrosis of sarcoma in mice. Later, Old and Carswell isolated tumor necrosis factor (TNF) as an active mediator in LPS- or BCG-induced tumor necrosis. These and other discoveries restored Coley’s reputation. They were considered to provide a satisfactory answer to his observations, but despite all expectations, the cures obtained with MBV could not be replicated with isolated TNF-α or other cytokines. Nevertheless, these discoveries marked the beginning of an immunological...
Today, a far more comprehensive understanding of the human immune system and tumor immunology is present, as is a conceptual extension beyond the simple self-nonself model, permitting a better understanding of Coley’s results. Obviously, MBVs stimulated a complex cascade, a “perfect storm” of cytokines—among these, interleukin (IL)-2, interferon-α, TNF-α, and IL-12 and IL-19 are seen as critical—and of toll-like receptors and other pattern recognition receptor agonists, each of which plays a unique and vital role in the orchestration of the immune response. Both the innate and the adaptive immunity are decisive, and the tumor vasculature is involved. Critical in the mediation of MBV effects is probably the activation of resting dendritic cells—via induction of cytokines and inflammatory factors with co-stimulatory activity. This leads to an activation of anergic T-cells, paralleled by a possible direct damage of cancer cells, inducing an improved supply of tumor antigens.

A growing body of literature shows the complex modifying and orchestrating effects of fever and elevated temperature on the host response, immune cells, cytokines, antimicrobial defense, antitumor activity, and immune surveillance. For instance, fever and hyperthermia activate the heat-shock response, inducing heat-shock proteins; these can then activate dendritic cells and transform them into mature antigen-presenting cells, which then potentiate the immune recognition of antigens. Furthermore, hyperthermia improves immune surveillance by activating NK-cells and T-cells and increasing trafficking of dendritic cells into lymph nodes. Hyperthermia also directly induces tumor cell necrosis and apoptosis. In patients with sarcoma, hyperthermia increases the antitumoral efficacy of chemotherapy and radiotherapy.

It is notable that erysipelas in particular is connected with spontaneous or induced tumor remission. Heat-killed, however, these gram-positive bacteria are hardly effective at all. In MBV, the gram-negative Serratia far outweigh the streptococci by an estimated factor of 7300:1, and in animal experiments, the curative and toxic effects are connected to Serratia whereas heat-killed streptococci alone are neither therapeutic nor toxic. Additionally, further research centered on endotoxins that are not present in gram-positive streptococci. During a fulminant erysipelas attack, possibly, toxins are released continuously and fever may last for 1 to 2 weeks whereas the bacterial toxins were applied as a bolus. For the tumor responses obtained with living streptococci, a plasminogen activator may have played a role, particularly streptokinase, which is produced by virulent streptococci.

It is remarkable that tumor remissions by MBV required continuous and aggressive administration of bacterial vaccines, eliciting a cascade of cytokines over an extended period of time—days and weeks. The full therapeutic effects achieved with these vaccines may not be reproducible when applying just 1 or 2 recombinant cytokines. Though Coley’s cures involved the same immune mediators as modern stand-alone immune therapies, they used all of them in concert over an extended time and in the relevant part of the body. One should also bear in mind that a century ago, high exposure to tuberculosis was omnipresent and may have substantially contributed to higher effectiveness of the toxins.

The question arises whether sarcomas respond better and more dramatically to erysipelas and MBV than carcinomas. They are overrepresented in erysipelas-induced tumor remissions. Mostly sarcomas were treated with MBV, especially soft-tissue sarcoma. Perhaps Coley, being the head of the New York Cancer Hospital's Bone Cancer Department, had greater access to sarcoma patients and was not often consulted by carcinoma patients. His own comments on this issue are inconsistent. There are, in fact, a variety of reports of complete remissions of carcinomas as well, mainly from other physicians. Still, the hypothesis was raised that the mesodermal (mesenchymal) embryonic origin of sarcoma tissue might make these tumors more immunogenic.

CONCLUSION

Altogether, the responses to fever therapy, spontaneous remissions in the course of infectious diseases, and the observation of the inverse correlation of acute febrile infections and incidence of cancer are remarkable. Still, deciphering the optimal tuning of host response and immune surveillance is far from being solved. A systemic concept is probably needed to understand the orchestrated cytokine and cellular storm resulting in the cures; otherwise, we might forever be left perplexed by the multitude of different kinds of cellular and molecular interactions.

What is remarkable is that Coley developed the treatment not as we are used to—via “research and development” by the laboratories of biotech industry—but quite differently: through careful clinical observation of hundreds of patients and thorough knowledge of medical and scientific literature combined with critical reflection. Coley was the epitome of a clinician scientist, one of those pioneering individual physicians who made the seminal discoveries, especially in the golden age between 1930 and 1965, that irrevocably changed medicine by bringing us, for instance, sulphonamides, penicillin, cephalosporins, neuroleptics, antipetals, and steroids. Since then, clinical drug research has moved into the laboratories and the pharmaceutical industry and is presently experiencing an insufficiency crisis. The strengths of those clinical champions are today remembered and called for again, and so are their virtues. Like Coley, they were proficient in their clinical work, guided by practical scientific thinking, open to the unexpected, and driven by the desire to cure patients.
72. Abel U, Becker N, Angerer R, et al. Common infections in the history of cancer patients and controls. J Cancer Res Clin Oncol. 1991;117(3):339-44.
73. Klaiber GC, Geissler O, Hafkamp B, Feher K. Whole-viruses and malignancies: a result of a case-control study. Malignana Res. 1992 Sep;2(3):207-12.
74. Wrensch M, Weinberg A, Wiencsek J, et al. Does prior infection with varicella zoster virus influence risk of adult glialoma? Am J Epidemiol. 1997 Apr 15;145(8):694-7.
75. Aizou MU, Beker EU, Hafkamp B, et al. Postoperative fever-range thermal stress. Immunol Res. 2010 Mar;46(1-3):177-88.
76. Kolmoll KE, Pfahlberg A, Mastrangelo G, et al. Infections and melanoma risk: a results of a multicentre EORTC clinical study. Malignana Res. 1999 Oct;13(5):311-9.
77. Schlehofer B, Blattert M, Preston-Martin S, et al. Role of medical history in brain tumour development. Results from the international adult brain tumour study. Int J Epidemiol. 1999 Jul;28(4):624-30.
78. Hoffmann C, Rosenberger A, Truger W, Bluth M. Childhood diseases, infectious diseases, and fever as potential risk factors for cancer? Forsch Komplementmed Klass Naturheilkd. 2002 Dec;9(6):324-30; discussion 321-2. German.
79. Meneguz F, Olhain AF, Neglia JP, Pollack BH, Bondy ML. Day care, childhood infections, and risk of neuroblastoma. Am J Epidemiol. 2004 May 1;159(9):843-54.
80. Roman E, Simpson J, Ansell P, et al. Childhood acute lymphoblastic leukemia and infections in the first year of life: a report from the United Kingdom Childhood Cancer Study. Am J Epidemiol. 2007 Mar 1;165(5):506-14.
81. Cardwell CR, McKinney PA, Patterson CC, Murray LJ. Infections in early life and childhood leukemia risk: a UK case-control study of general practitioner records. Br J Cancer. 2008 Nov 4;99(5):759-65.
82. McArthur AC, McBride ML, Spinelli JJ, et al. Lung cancer and postoperative empyema. Eur J Cancer. 1983 Apr;26(4):263-8.
83. Ruckdeschel JC, Codish SD, Stranaham A, McKneally MF. Postoperative empyema after pulmonary resection for bronchogenic carcinoma. Br Med J. 1978 Nov;2(6114):1201-3.
84. Cramer DW, Finn OJ. Epidemiologic perspective on immune-surveillance in cancer. Curr Opin Immunol. 2011 Apr;23(2):265-71.
85. Vestergaard H, Vestergaard T, Wohlfahrt J, Hjalgrim H, Melbye M. Tonsillitis, tonsillectomy and risk of childhood leukaemia. Int J Epidemiol. 2010 Jun;39(3):718-32.
86. Rudant J, Orsi L, Menegaux F, et al. Childhood acute lymphoblastic leukemia. Oncologist. 2006 Dec;11(6):684-9.
87. Wrotek S, Kamecki K, Skawrowski L, Kusak W. Cancer patients report a history of fewer fevers during infections than healthy controls. J Preclin Clin Res. 2009;3(1):31-5.
88. Urayama KY, Menegaux F, Buffler PA, Gallagher ER, Ayoob JM, Ma X. A meta-analysis of the infection, immune system activity and risk of neuroblastoma. Am J Epidemiol. 2004 May 1;159(9):843-51.
89. McArthur AC, McBride ML, Spinelli JJ, et al. Lung cancer and postoperative empyema. Eur J Cancer. 1983 Apr;26(4):263-8.
90. Ruckdeschel JC, Codish SD, Stranaham A, McKneally MF. Postoperative empyema after pulmonary resection for bronchogenic carcinoma. Br Med J. 1978 Nov;2(6114):1201-3.
91. Menegaux F, Olshain AF, Neglia JP, Pollack BH, Bondy ML. Results of the surgical treatment of broncho-vascular carcinoma. Dis Colon Rectum. 1985 Feb;28(2):94-5.
92. Mehta A, Neglia JP, Pollack BH, Bondy ML. Does a local postoperative infection improve the prognosis of cancer patients? Int J Radiat Oncol Biol Phys. 1979 Feb;5(2):125-9.
93. Nossal GJ. The case history of Mr. TJ. Terminal patient or still curable? Immunol Today. 1991 Jul 1;12(7):280-5.
94. Wrensch M, Weinberg A, Wiencke J, et al. Does prior infection with varicella-zoster virus influence risk of adult glialoma? Am J Epidemiol. 1997 Apr 15;145(8):694-7.
95. van den Burg H, Blommaart E, Bergh A, et al. A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br J Cancer. 1976 Mar;29(3):341-59.
96. Carrell EA, Old LJ, Kassel RL, Green S, Nuovo G. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A. 1975 Jul 1;72(12):4632-6.
97. Hutt M, Hildabrandt B, Svennevaas G, et al. Hyperthermia in combined treatment of cancer. Lancet Oncol. 2002 Aug;3(8):487-9.
98. Isels RD, Lindner LR, Verweij J, et al. Neoadjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol. 2010 Jun;11(6):561-70.
99. Zacharski LR, Suhktame VP, Coley’s toxin revisited: immunotherapy or plasminogen activator therapy of cancer? J Thromb Haemost. 2005 Mar;3(3):288.
100. Issels RD, Lindner LR, Verweij J, et al. Neoadjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol. 2010 Jun;11(6):561-70.
101. Shaywitz DA, Ausiello DA. Preserving creativity in medicine. PLoS Med. 2004 Apr 1;1(3):e34.
102. Horrobin DF. Effective clinical innovation: an ethical imperative. Lancet. 2002 May 17;359(9252):1857-8.
103. Nossal GJ. The truth about drug companies. New York: Random House; 2004.
104. Drews J. In quest of tomorrow’s medicines. Berlin, Heidelberg, New York: Springer; 2003.
105. Old LJ. Tumor necrosis factor (TNF). Science. 1985 Nov 8;230(4726):630-2.
106. Hunger HB, Animal tumor models and their relevance to human tumor immunology. J Biomed Sci. 1992 Mar;1(3):27-39.
107. Sporn MB, Roberts AB. Peptide growth factors are multifunctional. Nature. 1988 Mar 17;331(6164):227-9.
108. Immune surveillance in context. J Cell Biol. 1994 Dec 19;125(8):1531-6.
109. Silverstein AM. A history of immunology. San Diego, New York, Boston, London, Sydney, Tokyo, Toronto: Academic Press; 1989.
110. Nossal GJ. The truth about drug companies. New York: Random House; 2004.
111. Nathan C, Sporn MB. Cytokines in context. J Cell Biol. 1992 Jan 13;119(1):81-6.
112. Old LJ. Tumor necrosis factor (TNF). Science. 1985 Nov 8;230(4726):630-2.
113. Decker WK, Saltz A. Bismuthomnadsfuzzytory for the neoplastic and infectious disease. Coley’s legacy revisited. Cytokine Growth Factor Rev. 2009 Aug;20(4):271-81.
114. Sherr MJ, Perthual A, Shovelton T. Chemical treatment of tumors. V. Isolation of the hemorrhage-producing fraction from Serratia marcescens (Bacillus prodigiosus) culture filtrate. J Natl Cancer Inst. 1943;8(1):47-9.
115. Carswell EA, Old LJ, Kassel RL, Green S, Nuovo G. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A. 1975 Jul 1;72(12):4632-6.